Table 2.

Sex‐Wise 4‐Year Outcomes in Patients at HBR

	Women at HBR (n=821)	Men at HBR (n=1576)	Log‐Rank P Value	Unadjusted HR (95% CI)	P Value	Adjusted HR (95% CI)	P Value
MACE	12.2%	12.6%	0.82	0.97 (0.75–1.25)	0.82	0.64 (0.32–1.28)	0.20
All‐cause death	18.4%	18.4%	0.90	0.99 (0.80–1.21)	0.90	0.55 (0.30–1.03)	0.06
Cardiac death	9.7%	9.8%	0.88	0.98 (0.73–1.30)	0.88	0.52 (0.23–1.20)	0.13
Noncardiac death	9.7%	9.6%	0.98	1.00 (0.74–1.34)	0.98	0.63 (0.24–1.63)	0.34
MI	4.3%	3.9%	0.51	1.16 (0.75–1.80)	0.51	1.61 (0.55–4.72)	0.38
Definite/Probable ST	1.5%	2.0%	0.41	0.75 (0.37–1.50)	0.41	0.64 (0.10–3.93)	0.63
Major bleeding	10.8%	6.2%	<0.0001	1.81 (1.34–2.43)	<0.0001	0.92 (0.41–2.08)	0.84
ID‐TLR	11.1%	7.4%	0.004	1.55 (1.16–2.08)	0.003	2.24 (1.07–4.68)	0.03

Adjusted hazard ratio (HR) adjusted for age 75 years and older, diabetes mellitus, smoker, hypertension, hyperlipidemia, prior myocardial infarction (MI), prior cardiac intervention, left ventricular ejection fraction <30%, acute coronary syndrome, multivessel disease, B2/C lesion. Major adverse cardiac event (MACE) is a composite of cardiac death, MI, or definite/probable stent thrombosis (ST). HBR indicates high bleeding risk; and ID‐TLR, ischemia‐driven target lesion revascularization.